FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
The audit was completed with zero critical and zero major observations
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The U.S. FDA issued a Form 483 with five observations
Subscribe To Our Newsletter & Stay Updated